FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4200253395> ?p ?o ?g. }

• W4200253395 endingPage "533" @default.
• W4200253395 startingPage "527" @default.
• W4200253395 abstract "Antimicrobial resistance is one of the top 10 global public-health threats. Especially high rates of resistance have been reported for isolates from ICU patients, requiring expanded treatment options in this setting. We evaluated the activity of ceftolozane/tazobactam and comparators against Gram-negative isolates collected from patients with lower respiratory tract infections (LRTIs) in ICUs in seven Asian countries. In 2017–2019, up to 100 consecutive, aerobic Gram-negative LRTI isolates were collected per year at each of 37 hospitals. MICs were determined using the Clinical and Laboratory Standards Institute reference broth microdilution method. Overall, ceftolozane/tazobactam was active against 72% of 1408 Enterobacterales and 86% of 761 Pseudomonas aeruginosa isolates. Susceptibility to the non-carbapenem β-lactam comparators, including piperacillin/tazobactam, was 52–67% among Enterobacterales isolates, and the activity of all β-lactam comparators, including meropenem, was 57–70% among P. aeruginosa. Ceftolozane/tazobactam maintained activity against 61% of meropenem-nonsusceptible and 64% of piperacillin/tazobactam-nonsusceptible P. aeruginosa. At the country-level, ceftolozane/tazobactam activity ranged from >90% against Enterobacterales from Hong Kong and South Korea to <64% in Thailand and Vietnam, and from >90% against P. aeruginosa from South Korea, Malaysia, Philippines and Taiwan to <75% in Thailand and Vietnam. Correspondingly, the proportions of carbapenemase-positive isolates among Enterobacterales and P. aeruginosa isolates were highest in Thailand and Vietnam. Ceftolozane/tazobactam provides a potential treatment option for ICU patients in Asia, which is especially important considering the reduced activity of commonly used β-lactams against the studied ICU isolates. Knowledge of local resistance patterns should inform empirical therapy decision-making." @default.
• W4200253395 created "2021-12-31" @default.
• W4200253395 creator A5017159626 @default.
• W4200253395 creator A5035614223 @default.
• W4200253395 creator A5037643218 @default.
• W4200253395 creator A5038009031 @default.
• W4200253395 creator A5042149117 @default.
• W4200253395 creator A5042818728 @default.
• W4200253395 creator A5066677972 @default.
• W4200253395 creator A5089366807 @default.
• W4200253395 date "2022-06-01" @default.
• W4200253395 modified "2023-09-28" @default.
• W4200253395 title "In vitro activity of ceftolozane/tazobactam against Gram‐negative isolates collected from ICU patients with lower respiratory tract infections in seven Asian countries—SMART 2017–2019" @default.
• W4200253395 cites W1618166169 @default.
• W4200253395 cites W1936381283 @default.
• W4200253395 cites W1980773379 @default.
• W4200253395 cites W2053129457 @default.
• W4200253395 cites W2055329510 @default.
• W4200253395 cites W2157710626 @default.
• W4200253395 cites W2189335966 @default.
• W4200253395 cites W2408072278 @default.
• W4200253395 cites W2473016454 @default.
• W4200253395 cites W2533596066 @default.
• W4200253395 cites W2595267236 @default.
• W4200253395 cites W2602667098 @default.
• W4200253395 cites W2615674137 @default.
• W4200253395 cites W2752537900 @default.
• W4200253395 cites W2756597151 @default.
• W4200253395 cites W2762251864 @default.
• W4200253395 cites W2800004776 @default.
• W4200253395 cites W2802188865 @default.
• W4200253395 cites W2807183168 @default.
• W4200253395 cites W2889701556 @default.
• W4200253395 cites W2903000876 @default.
• W4200253395 cites W2962695320 @default.
• W4200253395 cites W2973651545 @default.
• W4200253395 cites W2986744786 @default.
• W4200253395 cites W2995278092 @default.
• W4200253395 cites W2999349080 @default.
• W4200253395 cites W3042826286 @default.
• W4200253395 doi "https://doi.org/10.1016/j.jgar.2021.11.011" @default.
• W4200253395 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/34896336" @default.
• W4200253395 hasPublicationYear "2022" @default.
• W4200253395 type Work @default.
• W4200253395 citedByCount "3" @default.
• W4200253395 countsByYear W42002533952022 @default.
• W4200253395 countsByYear W42002533952023 @default.
• W4200253395 crossrefType "journal-article" @default.
• W4200253395 hasAuthorship W4200253395A5017159626 @default.
• W4200253395 hasAuthorship W4200253395A5035614223 @default.
• W4200253395 hasAuthorship W4200253395A5037643218 @default.
• W4200253395 hasAuthorship W4200253395A5038009031 @default.
• W4200253395 hasAuthorship W4200253395A5042149117 @default.
• W4200253395 hasAuthorship W4200253395A5042818728 @default.
• W4200253395 hasAuthorship W4200253395A5066677972 @default.
• W4200253395 hasAuthorship W4200253395A5089366807 @default.
• W4200253395 hasBestOaLocation W42002533951 @default.
• W4200253395 hasConcept C176947019 @default.
• W4200253395 hasConcept C2777637488 @default.
• W4200253395 hasConcept C2777858937 @default.
• W4200253395 hasConcept C2778193466 @default.
• W4200253395 hasConcept C2778266534 @default.
• W4200253395 hasConcept C2779375183 @default.
• W4200253395 hasConcept C2780950330 @default.
• W4200253395 hasConcept C4937899 @default.
• W4200253395 hasConcept C501593827 @default.
• W4200253395 hasConcept C523546767 @default.
• W4200253395 hasConcept C54355233 @default.
• W4200253395 hasConcept C71924100 @default.
• W4200253395 hasConcept C86803240 @default.
• W4200253395 hasConcept C89423630 @default.
• W4200253395 hasConcept C94665300 @default.
• W4200253395 hasConceptScore W4200253395C176947019 @default.
• W4200253395 hasConceptScore W4200253395C2777637488 @default.
• W4200253395 hasConceptScore W4200253395C2777858937 @default.
• W4200253395 hasConceptScore W4200253395C2778193466 @default.
• W4200253395 hasConceptScore W4200253395C2778266534 @default.
• W4200253395 hasConceptScore W4200253395C2779375183 @default.
• W4200253395 hasConceptScore W4200253395C2780950330 @default.
• W4200253395 hasConceptScore W4200253395C4937899 @default.
• W4200253395 hasConceptScore W4200253395C501593827 @default.
• W4200253395 hasConceptScore W4200253395C523546767 @default.
• W4200253395 hasConceptScore W4200253395C54355233 @default.
• W4200253395 hasConceptScore W4200253395C71924100 @default.
• W4200253395 hasConceptScore W4200253395C86803240 @default.
• W4200253395 hasConceptScore W4200253395C89423630 @default.
• W4200253395 hasConceptScore W4200253395C94665300 @default.
• W4200253395 hasFunder F4320307776 @default.
• W4200253395 hasLocation W42002533951 @default.
• W4200253395 hasLocation W42002533952 @default.
• W4200253395 hasOpenAccess W4200253395 @default.
• W4200253395 hasPrimaryLocation W42002533951 @default.
• W4200253395 hasRelatedWork W2013041033 @default.
• W4200253395 hasRelatedWork W2041719551 @default.
• W4200253395 hasRelatedWork W2782181787 @default.
• W4200253395 hasRelatedWork W2992971854 @default.
• W4200253395 hasRelatedWork W3138687476 @default.
• W4200253395 hasRelatedWork W3202593657 @default.

• next